Takeda Pharmaceutical Co. is capturing interest from a variety of perspectives in the market.
Opinions remain
divided: some consider it undervalued and a great value stock for income investors, while others see it ripe for a turnaround after a dip in stock prices.
Short sellers suggest it's a cheaper pharmaceutical stock to buy. Several asset management companies, including
Oppenheimer,
Summit Global Investments, and
Creative Planning, have
revised their positions with regard to Takeda.
Joint ventures and
mergers, such as the merger with a subsidiary, have been announced, pointing to a proactive strategy despite the annual profit slump. The company also continues to be an active player in the development of new treatments. However, there are some areas of concern, such as Takeda's
seizure drug falling short on meeting its main goal in late-stage studies, and the reduction of the company's full-year profit forecast.
Takeda Pharmaceutical Stocks News Analytics from Mon, 09 Jan 2017 08:00:00 GMT to Sun, 17 Nov 2024 09:45:43 GMT -
Rating 4
- Innovation 1
- Information 7
- Rumor -3